SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-004537 to IMMUTEP Ltd (IMMP) (CIK 0001506184) (IMMP)

IMMUTEP Ltd (IMMP) (CIK 0001506184)
Date: May 2, 2023 · CIK: 0001506184 · Accession: 0000000000-23-004537

AI Filing Summary & Sentiment

File numbers found in text: 333-271484

Date
May 2, 2023
Author
Not clearly detected
Form
UPLOAD
Company
IMMUTEP Ltd (IMMP) (CIK 0001506184)

Letter

United States securities and exchange commission logo May 2, 2023 Deanne Miller Chief Operating Officer, General Counsel & Company Secretary IMMUTEP Ltd Level 33, Australia Square 264 George Street Sydney, NSW 2000, Australia Re:IMMUTEP Ltd Registration Statement on Form F-3 Filed April 28, 2023 File No. 333-271484 Dear Deanne Miller: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Reilly

Show Raw Text
United States securities and exchange commission logo
May 2, 2023
Deanne Miller
Chief Operating Officer, General Counsel & Company Secretary
IMMUTEP Ltd
Level 33, Australia Square
264 George Street
Sydney, NSW 2000, Australia
Re:IMMUTEP Ltd
Registration Statement on Form F-3
Filed April 28, 2023
File No. 333-271484
Dear Deanne Miller:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Andrew Reilly